Skip to main content
Erschienen in: Investigational New Drugs 2/2008

01.04.2008 | Preclinical Studies

Topical henna for capecitabine induced hand–foot syndrome

verfasst von: Idris Yucel, Gonullu Guzin

Erschienen in: Investigational New Drugs | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Summary

Capecitabine is a chemotherapeutic drug for use in cancers. Hand–foot syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna (Lawsonia inermis) is a traditionally used plant of Middle-East that is applied on hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna.
Literatur
1.
Zurück zum Zitat Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem 8:1697–1706PubMedCrossRef Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem 8:1697–1706PubMedCrossRef
2.
Zurück zum Zitat Marsé H, Van Cutsem E, Grothey A, Valverde S (2004) Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8:16–30CrossRef Marsé H, Van Cutsem E, Grothey A, Valverde S (2004) Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8:16–30CrossRef
3.
Zurück zum Zitat Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar–plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13:1781–1783PubMed Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar–plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13:1781–1783PubMed
4.
Zurück zum Zitat Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand–foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169–2173PubMedCrossRef Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand–foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169–2173PubMedCrossRef
5.
Zurück zum Zitat Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar–plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303–306PubMedCrossRef Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar–plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303–306PubMedCrossRef
6.
Zurück zum Zitat Komamura H, Higashiyama M, Hashimoto K, Takeda K, Kimura H, Tani Y (1995) Three cases of chemotherapy-induced acral erythema. J Dermatol 22:116–121PubMed Komamura H, Higashiyama M, Hashimoto K, Takeda K, Kimura H, Tani Y (1995) Three cases of chemotherapy-induced acral erythema. J Dermatol 22:116–121PubMed
7.
Zurück zum Zitat Mortimer JE, Lauman MK, Tan B (2003) Pyridoxine treatment and prevention of hand–foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 9:161–166CrossRef Mortimer JE, Lauman MK, Tan B (2003) Pyridoxine treatment and prevention of hand–foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 9:161–166CrossRef
8.
Zurück zum Zitat Kandil HH, al-Ghanem MM, Sarwat MA, al-Thallab FS (1996) Henna (Lawsonia inermis Linn.) inducing haemolysis among G6PD-deficient newborns. A new clinical observation. Ann Trop Paediatr 16:287–291PubMed Kandil HH, al-Ghanem MM, Sarwat MA, al-Thallab FS (1996) Henna (Lawsonia inermis Linn.) inducing haemolysis among G6PD-deficient newborns. A new clinical observation. Ann Trop Paediatr 16:287–291PubMed
9.
Zurück zum Zitat Mikhaeil BR, Badria FA, Maatooq GT, Amer MM (2004) Antioxidant and immunomodulatory constituents of henna leaves. Z Naturforsch [C] 59:468–476 Mikhaeil BR, Badria FA, Maatooq GT, Amer MM (2004) Antioxidant and immunomodulatory constituents of henna leaves. Z Naturforsch [C] 59:468–476
10.
Zurück zum Zitat Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMed Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMed
11.
Zurück zum Zitat Lassere Y, Hoff P (2004) Management of hand–foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8:31–40CrossRef Lassere Y, Hoff P (2004) Management of hand–foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8:31–40CrossRef
12.
Zurück zum Zitat Mrozek-Orlowski ME, Frye DK, Sanborn Hm (1999) Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nursing Forum 26:753–762 Mrozek-Orlowski ME, Frye DK, Sanborn Hm (1999) Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nursing Forum 26:753–762
13.
Zurück zum Zitat Gerbrecht BM (2003) Current Canadian experience with capecitabine. Cancer Nursing 26:161–167PubMedCrossRef Gerbrecht BM (2003) Current Canadian experience with capecitabine. Cancer Nursing 26:161–167PubMedCrossRef
14.
Zurück zum Zitat Fabian CJ, Molina R, Slavik M, Dahlberg S, Girl S, Stephens R (1990) Pyridoxine therapy for palmar–plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57–63PubMedCrossRef Fabian CJ, Molina R, Slavik M, Dahlberg S, Girl S, Stephens R (1990) Pyridoxine therapy for palmar–plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57–63PubMedCrossRef
15.
Zurück zum Zitat Ali BH, Bashir AK, Tanira MO (1995) Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology 51:356–363PubMedCrossRef Ali BH, Bashir AK, Tanira MO (1995) Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology 51:356–363PubMedCrossRef
Metadaten
Titel
Topical henna for capecitabine induced hand–foot syndrome
verfasst von
Idris Yucel
Gonullu Guzin
Publikationsdatum
01.04.2008
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 2/2008
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-007-9082-3

Weitere Artikel der Ausgabe 2/2008

Investigational New Drugs 2/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.